Lu et al, 2022

HIV epigenetic landscape in macrophages

Epigenetic Landscape of HIV Infection in Primary Human Macrophage

Fang Lu¹, Yanjie Yi², Olga Vladimirova¹, Urvi Zhankharia², Ronald G. Collman^{2,*}, and Paul M. Lieberman^{1,*}

¹The Wistar Institute, Philadelphia, PA 19104

²University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

*Corresponding Authors: Lieberman@wistar.org; collmanr@pennmedicine.upenn.edu

Running Title: HIV epigenetic landscape in macrophages

Keywords: HIV, latency, macrophage, microglia, histone, chromatin, DNA methylation, hydroxymethylation

Abstract

HIV-infected macrophages are long-lived cells that sustain persistent virus expression, which is both a barrier to viral eradication and contributor to neurological complications in patients despite antiretroviral therapy (ART). To better understand the regulation of HIV in macrophages, we compared HIV infected primary human monocyte derived macrophages (MDM) to acutely infected primary CD4 T cells and Jurkat cells latently infected with HIV (JLAT 8.4). HIV genomes in MDM were actively transcribed despite enrichment with heterochromatin-associated H3K9me3 across the complete HIV genome in combination with elevated activation marks of H3K9ac and H3K27ac at the LTR. Macrophage patterns contrasted with JLAT cells, which showed conventional bivalent H3K4me3/H3K27me3, and acutely infected CD4 T cells, which showed an intermediate epigenotype. 5'-methylcytosine (5mC) was enriched across the HIV genome in latently infected JLAT cells, while 5'-hydroxymethylcytosine (5hmc) was enriched in CD4 and MDM. HIV infection induced multinucleation of MDMs along with DNA damage associate p53 phosphorylation, as well as loss of TET2 and the nuclear redistribution of 5-hydroxymethylation. Taken together, our findings suggest that HIV induces a unique macrophage nuclear and transcriptional profile, and viral genomes are maintained in a non-canonical bivalent epigenetic state.

Importance

Macrophages serve as a reservoir for long-term persistence and chronic production of HIV. We found an atypical epigenetic control of HIV in macrophages marked by heterochromatic H3K9me3 despite active viral transcription. HIV infection induced changes in macrophage nuclear morphology and epigenetic regulatory factors. These findings may identify new mechanisms to control chronic HIV expression in infected macrophage.

Introduction

HIV results in lifelong infection requiring continuous antiretroviral therapy (ART) to suppress viral replication and prevent immune deficiency (1). A major barrier to cure is the existence of long-lived infected cells that persist during ART. Multiple anatomic sites may contribute to viral persistence including blood, lymphoid tissue, gut-associated lymphoid tissue, bone marrow, and brain (2-4). While most attention has focused on CD4⁺ T cell reservoirs, myeloid cells are well-established to harbor virus in the CNS, where macrophages and microglia are the principal infected cell type (5-7). Functional cure therefore requires attention not only to CD4⁺ T cell reservoirs but to other cells, including myeloid reservoirs.

Monocytes are generally resistant to HIV infection but become permissive as they mature into macrophages (8, 9). Macrophages are thus terminally differentiated non-dividing cells yet susceptible to robust HIV infection (10, 11). This feature differentiates them from T cells, which require activation and cell proliferation to become robustly susceptible in vitro (although limited low-level infection of resting T cells may be achieved in some models (12-14)). Thus, macrophage infection and establishment of integrated provirus occurs in the context of a unique cellular microenvironment relative to T cells, particularly with regards to chromatin structure. Another distinguishing feature of macrophage infection is that they are long-lived cells yet resistant to HIV-induced killing, and productively infected macrophages persist for prolonged periods, unlike activated CD4⁺ T cells that are killed by active virus replication (15-17). This feature enables infected myeloid cells to serve as long-term reservoirs in vivo, particularly in the CNS (18-21). Finally, while the resting CD4⁺ T cell long-term reservoir is typically thought of as latent, low-level virus expression generally persists throughout the lifespan of infected macrophages (18, 22-24). Indeed persistent low level virus expression from long-lived infected brain macrophages is thought to be a driver of neurological complications that occur in infected people despite ART (25, 26). Thus, macrophages likely control HIV differently than CD4⁺ T cells

and studies of epigenetic control in T cell models may not be sufficient to understand persistent infection in differentiated primary macrophages.

Transcriptional and epigenetic regulation of HIV in T-cells has been studied extensively (27, 28). Transcriptional regulation occurs primarily at the 5' LTR and is mediated by various transcription factors that control the modification and positioning of nucleosomes that restrict transcription initiation and elongation (27, 29, 30). In contrast to T cells, less is known about epigenetic factors that control HIV infection in macrophages. Here, we investigate epigenetic features, including active and repressive histone marks and DNA methylation and hydroxymethylation status across the HIV genome in infected primary human monocyte-derived macrophages (MDMs) that regulate HIV genome in post-integration latency. We compare MDMs to productively infected primary CD4⁺ T cells, and also with an established latency model in Jurkat T cells using JLAT cells. Our results revealed surprising non-canonical bivalent chromatin structures of HIV genome in primary infected macrophages.

Results

Epigenetic profiles of HIV genomes in primary macrophages, primary CD4 T cells and latent cell line JLAT.

The epigenetic modification of histones associated with HIV genomes in MDM, CD4 T cells, or latently infected T-cell line JLAT 8.4 was investigated by ChIP-qPCR assay using primers sampling regions across the entire viral genome (**Fig. 1**). Primary MDM and CD4 T cells were infected with the brain-derived macrophage-tropic HIV-1 primary isolate YU2 (31), while JLAT 8.4 cells carry a single clonally integrated HIV genome derived from a prototype strain (32). We assayed for histone H3K4me3, H3K9me3, H3K9ac, H3K9me2, H3K27ac, and H3K27me3. Total histone H3 and IgG occupancy was also analyzed by ChIP-qPCR (**Supplemental Fig S1**).

We observed significant differences in the pattern of histone modification between each of these HIV infection models. H3K4me3, a euchromatic mark associated with most transcriptional start sites, was enriched at site B in MDM and T cells, and in JLAT 8.4 at Nuc_0, site A and site S within the nef region and LTR. Nucleosome positions have been well characterized for HIV LTR in JLAT cells (33, 34). H3K9me3, a mark associated with constitutive heterochromatin, was highly enriched across the entire HIV genome in MDM (approaching 20% input), while relatively lower levels were observed in latently infected JLAT 8.4, and intermediate levels in CD4 T cells. H3K27me3, a facultative heterochromatic mark associated with polycomb-mediated repression, was enriched in JLAT 8.4 at Nuc 1 and site B, as well as within the body of the genome within the env gene (P and Q regions). H3K9ac was detected in the Nuc 0 and 1, and site B in MDM, with lower levels in JLAT 8.4 and CD4 T cells. Controls for H3K4me3 and H3K9ac were enriched at active cellular genes Actin and GAPDH as expected, and heterochromatic marks for H3K9me3 or H3K27me3 were enriched at telomeric sites (10q CTCF and TERRA) as expected (with the exception that JLAT 8.4 lacked H3K27me3 enrichment at telomeres). IgG levels were generally below threshold significance at all primer positions with the exception of Nuc 1 in all three cells and positions G, P, Q in JLAT 8.4 which showed a low background signal (**Supplemental Fig S1**). These findings indicate that HIV genomes in MDM are subject to distinct histone modification patterns compared to acute and latent CD4 T cell infection models. We also note that some of these epigenetic marks are enriched in HIV regions outside of the LTR.

Atypical bivalent histone modification of the MDM LTR. To further explore the ChIP data, we re-analyzed the histone modifications focusing only on the LTR and adjacent nucleosome 2 (site B) for each infection model (**Fig. 2**). We observed that the LTR in MDM was highly enriched with histone H3K9me3 and to a lesser extent with H3K27ac. The LTR in CD4 T cells also showed a relatively high enrichment of H3K9me3, as well as H3K9me2, and the highest

enrichment in H3K4me3 at site B, and the lowest density of total H3 relative to the other cell types tested. JLAT 8.4 cells were highly enriched for H3K4me3 at Nuc_0 and had low levels of H3K9me2 and H3K9me3. H3K27me3 was enriched at Nuc1 and site B in JLAT relative to the other cell types. This latter pattern of histone modifications has been reported previously for JLAT (35-37) and corresponds with bivalent (H3K4me3/K27me3) histone modification observed in some developmentally regulated genes and pluripotent stem cells (38). In contrast to JLAT, the H3K4me3 enrichment in CD4 peaked at site B, located close to nucleosome 2. The relatively high H3K9me3 seen in MDM and CD4 cells, combined with H3K4me3 in CD4 T cells and to a lesser extent in MDM, has been observed at lineage specific regulatory elements, such as methylation pause sites in adipocytes (39). The combination of H3K9me3 and H3K27ac that we find in MDM has also been observed for transposable elements in ES cells (40).

Antisense transcripts in infected MDM. Antisense transcripts are known to be a source of generating H3K9me3 (41), and antisense transcripts have been reported for HIV particularly during latent infection (42, 43). Therefore, we assayed for anti-sense HIV transcripts using HIV-specific antisense RT primers at nucleotide positions 15 (AS RT-2), 2944 (AS RT-1), and 7431 (AS RT-3) in conjunction with qPCR primer pairs positioned at 351-461 (primer 2), 3161-3275 (primer 1), 7846-7733 (primer 3) and 8333-8426 (primer 4) based on the YU2 HIV genome (**Fig. 3A**). Antisense transcripts were detected at all positions in YU2-infected MDM and CD4 T cells but not in uninfected control cells (**Fig. 3B**). Similarly, antisense transcripts were not detected in reactions lacking RT (**Fig. 3C**). The relative levels of anti-sense transcript in MDM and CD4 T cells correlated with the relative ratio of sense transcripts for *nef* and *tat* (**Fig. 3D**). These findings indicated that both MDM and CD4 T cells have measurable levels of anti-sense HIV and raise the possibility that antisense transcription contributes to H3K9me3 formation, as has been observed for many endogenous retroviruses (44).

Cytosine methylation and hydroxymethylation of HIV genomes. To investigate whether DNA modifications differed in MDM and CD4 T cell infection, we assessed the levels of cytosine methylation (5mC) and hydroxymethylation (5hmc) of HIV DNA in MDM, CD4 T cells, and JLAT 8.4 using MeDIP or hMeDIP assays (**Fig. 4**). We detected elevated levels of 5mC on the JLAT 8.4 genome, including locations at site B, which was previously identified as a CpG island adjacent to the 5'LTR in JLAT (35), and the 3' regions within the *env* gene (P, Q, R). Relatively low or undetectable levels of 5mc were found associated with HIV infection in MDM and CD4 T cells. In contrast, both MDM and CD4 T cells showed a broad pattern of hydroxymethylation (5hmc) across the HIV genomes, whereas this modification was mostly absent from JLAT 8.4. Cellular controls for 5mC and 5hMC were highly enriched at cellular telomeric positions, and absent in actively transcribed genes Actin and GAPDH. These findings indicate the 5mC is formed in long-term latently infected JLAT cells but is generally not formed during productive infection of primary MDM or CD4 T cells, while 5hmc forms during infection of MDM and CD4 T cells with actively transcribing HIV genomes.

Differential expression of histone and nuclear viral response proteins in MDM and CD4 T cells. To assess whether these epigenetic variations were associated with cell-type specific differences in global histone modifications, we assayed total cellular histone modification levels with or without HIV-1 YU2 infection by Western blot analysis (**Fig. 5A**). We found that histone levels were generally less abundant in MDM relative to CD4 (normalized to Actin and total protein), although these modifications did not change significantly upon HIV infection. Among the histone modifications, H3K9me2 appeared depleted in MDM relative to CD4, and H3K9me3 showed a slight increase (~1.47 fold) upon HIV infection in MDM. We next assayed chromatin proteins that have been implicated in nuclear antiviral functions (**Fig. 5B**). We found that PML had a different distribution of slow-mobility isoforms in HIV infected MDM that were not detectable in CD4 T cells. These slower mobility PML isoforms may reflect PML isoforms and

post-translational modifications induced by virus infections in the nucleus (45). Both DAXX and DNMT3A were less abundant in MDM relative to CD4 T cells, but were not affected by HIV infection. In contrast, the methylcytosine oxidase TET2 was downregulated in HIV-infected MDM, but not CD4 T cells. This is consistent with previous studies showing that TET2 is a target of ubiquitin-mediated degradation by HIV Vpr in macrophages (46, 47), and suggests this effect is cell type-specific. We also found that Lamin A/C is expressed at much higher levels in MDM relative to CD4, while the reverse occurs for Lamin B1 expression. These differences may reflect the very different nuclear morphology and cell-cycle properties of MDM and CD4 T cells. HIV also induced p53 in MDM, but not in CD4 T cells (**Fig. 5C**). And strikingly, we found that MDM had near undetectable levels of PARP1, although HIV induced total cellular levels of poly-ADP ribose (PAR), suggesting that other PARPs may be activated in MDM in response to HIV infection. Taken together, these findings underscore substantial differences in nuclear protein biology in MDM and CD4 T cells, and their distinct responses to HIV infection.

HIV induced changes in MDM nuclear organization. MDM form multinucleated and giant cells in response to activation signals and in response to HIV infection both *in vitro* and in the brain *in vivo* (8, 48-50). We examined the changes in MDM nuclear morphology before and after HIV infection, using immunofluorescence microscopy to detect nuclear proteins and viral p24 Gag antigen (**Fig. 6**). HIV infection led to a marked increase in multinucleated cells enriched with H3K4me3 (~2.0 fold) and 5-hmc (~1.6 fold) (**Fig. 6A, B, and E**). We also observed an increase in punctate PML and DAXX colocalized nuclear bodies in each of the multiple-nuclei in infected MDM (**Fig. 6C, D and E**). We also observed that 5hmc signal changed substantially upon HIV infection in MDM (**Fig. 6F**). In the absence of infection, most 5hmc appeared perinuclear, while after HIV infection 5hmc was strongly enriched in each of the nuclei of the multinucleated MDM. These findings demonstrate that HIV infection remodels

MDM nuclear morphology, induces an antiviral response increase in PML nuclear bodies, and induces a strong nuclear relocalization of 5hmc.

Discussion

While much is known about HIV infection and latency in CD4 T cells, relatively less is known about the regulation of HIV in macrophages. Here, we examined the epigenetic features of HIV in primary human MDMs, employing a brain-derived HIV-1 primary isolate relevant to *in vivo* infection, and compared it with CD4⁺ T cells and the latently infected T cell line JLAT 8.4. Our comparison suggests that MDM use different mechanisms than CD4⁺ T cells to regulate HIV infection. We found HIV sequences in MDM are enriched with H3K9me3 throughout the viral genome, with an atypical bivalent histone modification characterized by high H3K9me3 in combination with H3K27ac (**Fig.7**). We also observed that 5'-hydroxymethylated cytosine (5-hmc) was enriched across the HIV genome in MDM and CD4, but not in JLAT, which were elevated in 5-mc. These data suggest that the epigenetic regulatory features in MDMs are different than those observed in both productively infect CD4 T cells and latently infected JLAT cells, and potentially distinct from previously characterized macrophage activation states.

Our findings are similar to previous reports of H3K9me3-associated heterochromatin that was associated with silencing of HIV LTR post-integration (51, 52). However, in MDM infection where HIV is actively transcribing, the H3K9me3 does not appear to confer transcriptional silencing. In CD4 T cells, H3K9me3 formation was found to depend on the histone methyltransferase SUV39H1 or the SETDB1-associated HUSH complex (53). In microglial cells, transcription factor C/EBP alpha, co-repressor CTIP2, and histone demethylase LSD1 have all been implicated in the formation of silent heterochromatin at the HIV LTR (52, 54, 55). COUP-TF and CTIP2 were found to recruit HP1alpha and H3K9me3 methylation in microglial cells (23, 56, 57). HIC1 and HMGA1 were also found to be chromatin-associated repressors of

HIV transcription in microglial cells (58). Whether these same factors function to generate H3K9me3 in MDMs is unknown. Epigenetic control of HIV transcription and replication is also likely to depend on the surrounding chromatin environment. We noted that HIV genomic regions outside the LTR, and especially within the regions encompassing the env ORF, have distinguishing epigenetic marks. In JLAT 8.4, this region was enriched for H3K27me3 and 5-mc. This raises the possibility that regulatory control outside the 5' LTR may contribute to the epigenetic regulation of HIV.

DNA methylation is also known to contribute to HIV silencing of the 5' LTR in JLAT and CD4+ T cells (35, 59). We found high levels of 5mC at the LTR in JLAT, as expected, but no significant 5mC in MDM. On the other hand, 5hmc levels were enriched in MDM across the entire HIV genome. To our knowledge, hydroxymethylcytosine has not yet been described in the regulation of HIV in macrophage or T-cells. HIV Vpr has been shown to cause ubiquitin-mediated degradation of TET2 (46, 47), the major enzyme responsible for enzymatically converting methylcytosine to hydroxymethylcytosine in hematopoietic cells (60). Our data show that TET2 is selectively degraded in MDM infection, but not in CD4 T cells (**Fig. 5**). We also observed increased intensity and relocalization of 5hmc from the nuclear periphery to the nucleus in HIV infected MDMs (**Fig. 6**). A similar localization of 5hmc to the nuclear periphery was observed in developing mouse retinal photoreceptor cells (61). How the HIV-dependent degradation of TET2 is balanced with the enrichment and redistribution of 5hmc on the HIV genome remains to be elucidated.

Total levels of histone proteins were lower in MDMs, as were most modified histones, relative to CD4+ T cells. This may reflect the post-mitotic state of MDMs relatively to cycling CD4+ T cells. However, the amount of H3K9me3 relative to other histone modifications appeared to be higher in MDM. While HIV infection did not alter global levels of any histone modification, it did induce many other changes in MDM proteins. In addition to the loss of TET2, HIV induced several

modifications associated with viral infection and DNA damage response, including modification of PML, induction of p53, and the generation of PAR. PARP1 has been found to form a complex with Vpr (62), but our findings suggest that PARP1 is undetectable prior to HIV infection in MDM cells. Other PARPs, such as PARP2 or Tankyrase may be responsible for PARylation in MDM cells.

Imaging studies revealed that HIV infection leads to a large increase in multinucleated giant cells, which is well described *in vitro* and *in vivo*. These form in response to macrophage activation due to direct interaction with pathogens (63), or phagocytic substrates (64). For HIV-infected cells, multinucleate giant cells may also result from Env-mediated cell-cell fusion. More recent studies suggest that macrophage multinucleation can arise from mitotic polyploidy and chromothripsis, and not exclusively as a result of cellular fusions (65). Our findings are consistent with the induction of DNA damage based on the increase in phosphorylated p53 and PAR that correlates with the formation of the multinucleated macrophages after HIV infection.

HIV transcriptional regulation has been shown to be controlled primarily by factors that bind to the LTR and the TAR regions, including nucleosomes positioned in close proximity to the transcription start site. Recent studies suggested unintegrated HIV DNA, especially 2-LTR circles were associated with repressive chromatin structure (66, 67), and that circular HIV persists in macrophages since they are non-dividing cells (68). Most of the assays in this study do not distinguish between 2-LTR circles and integrated HIV provirus, so it remains possible that some of the epigenetic signals associated with the HIV genome in MDM are derived from the non-integrated 2-LTR circles. It is also known that most HIV genomes integrate into transcriptionally active loci in the cellular genome, and therefore are not subject to local heterochromatic repression. However, it is not fully known how long-term epigenetic suppression occurs in T-cells, nor how the H3K9me3 repressive chromatin is formed, especially in MDMs where HIV transcription is not silenced. Others have found that H3K9me3 can be

associated with transcriptional activation (69, 70) and mRNA elongation (71), especially when this histone modification paired with H3K9ac or H3K4me2 (72). H3K9me3 is also found coupled with H3K27ac at transposable elements that can be transcriptionally activated in some cell types and stress conditions (40). We provide evidence that HIV genomes have H3K9me3 distributed throughout the viral genome, and that antisense transcription occurs that may initiate at the 3' LTR. The detection of antisense transcription in MDM is consistent with the model that antisense transcripts can recruit factors that generate H3K9me3 heterochromatin (35, 36). Paradoxically, the elevated H3K9me3 in MDM does not correspond to transcriptional repression, suggesting that H3K9me3 may not serve as transcriptionally repressive heterochromatin in the context of the HIV genome in macrophage. It is likely that additional repressive factors that restrict RNA polymerase II function may be not fully operational at the HIV LTR in MDM infection.

Materials and Methods

Cells and viral infection. Monocytes were purified from healthy donors and cultured in Iscove's Modified Dulbecco's Medium (IMDM) containing 10% human AB serum with penicillin, streptomycin and 1% glutamine. Monocytes were maintained in culture for 7 days to allow differentiation into monocyte-derived macrophage (MDM) prior to HIV-1 infection. CD4 T cells were purified from healthy donors and cultured in RPMI1640 containing 10% FCS with penicillin, streptomycin and 1% glutamine. T cells were stimulated with 5 µg/ml phytohemagglutinin (PHA) for 3 days prior to HIV-1 infection, then treated with 10 ng/ml interleukin-2 (IL-2). Cell purification used negative selection employing the Rosette-Sep platform (Stemcell Technologies) and were carried out by the Penn CFAR Immunology Core. All data represent a minimum of three independent experiments using cells from different donors.

299

300 The brain-derived HIV-1 pYU2 infectious molecular clone (IMC) with all accessory genes intact
301 (31) was provided by Dr. B. Hahn (University of Pennsylvania), and infectious virus generated
302 by transfection of 293T cells. Virus was treated with DNase (to prevent inadvertent transfection
303 of residual plasmid during infections) and quantified by HIV-1 p24 Gag antigen by ELISA. To
304 enhance entry into CD4 T cells, the HIV-1 YU2 IMC was co-transfected with plasmid encoding
305 VSVg to generate mixed pseudotypes, harvested and quantified similarly. To enhance infection
306 of MDM in the Chromatin and DNA Immunoprecipitation (ChIP, DIP) experiments, transduction
307 with the Vpx protein of SIV was carried out. Vpx-containing pseudotype virions were generated
308 by co-transfecting 293T cells with plasmids encoding SIV Gag, SIV Vpx gene and VSVg (73),
309 provided by J. Skowronski (Case Western Reserve University). Viral particles were harvested 3
310 days later, quantified by SIV Gag p27 antigen by ELISA, and 3 ng of p27 was used for
311 transduction per 10^6 MDM at same day of HIV-1 infection. MDM at 7 days post-plating or CD4 T
312 cells 3 days post-PHA stimulation were infected with HIV-1 YU2 using 7 ng of viral p24 Gag
313 antigen per 10^6 MDM or 3.5 ng of viral p24 Gag antigen per 10^6 CD4 T cells. Cells were infected
314 by spinoculation at 1200 g for 2 hours at room temperature, and then maintained in culture until
315 analyzed.

316

317 For ChIP, MeDIP and hMeDIP assays, 50 nM of the RT inhibitor efavirenz (EFV) was added to
318 MDM 6 days post infection to restrict further rounds of re-infection and enable maximal
319 integration, or added to CD4 T cells 4 days post infection, then cells were cultured for additional
320 4 days before harvest. For RT-PCR, EFV was added to MDM cells 7 days post infection, cells
321 were then cultured for additional 7 days before harvest. EFV was added to CD4 T cells 2 days
322 post infection, then cells were cultured for additional 2 days before harvest. For Western blot
323 analysis, cells were harvested 7 days post infection.

324

Chromatin immunoprecipitation (ChIP)-qPCR assays. ChIP-qPCR assays were performed as described previously (74). Quantification of precipitated DNA was determined using real-time PCR and the delta Ct method for relative quantitation (ABI 7900HT Fast Real-Time PCR System). Rabbit IgG (2729S, Cell Signaling), anti-H3K4me3 (07-473, Millipore Sigma), H3K9me2 (C15410060, Diagenode), H3K9me3 (C15410056, Diagenode), H3K9ac (07-352, Millipore Sigma), H3K27me3 (C15410069, Diagenode), H3K27ac (ab4729, Abcam), and pan-histone H3 (07-690, Millipore Sigma) were used in ChIP assays. Primers for ChIP and DIP assays are listed in Supplemental Table S1.

MeDIP and hMeDIP assays. Total genomic DNA was purified using Wizard® Genomic DNA Purification Kit (Promega, A1120) then subjected to methylcytosine-DNA-immunoprecipitation (MeDIP) or hydroxymethylcytosine-DNA-IP (hMeDIP) assays. The MeDIP or hMeDIP assays were performed using MagMeDIP kit (Diagenode, C02010021) or hMeDIP kit (Diagenode, C02010031). Quantification of precipitated DNA was determined using real-time PCR and the delta Ct method for relative quantitation (ABI 7900HT Fast Real-Time PCR System).

Western blot assay. Rabbit anti-H3K4me3, H3K9me2, H3K9me3, H3K27me3 and pan histone H3 antibodies used in Western blotting were same as antibodies used in ChIP assays. Rabbit polyclonal anti-H3ac (06-599, Millipore Sigma), anti-H2B (07-371, Millipore Sigma), anti-Lamin B1 (12586S, Cell Signaling), anti-TET2 (21207-1-AP, Proteintech), anti-PARP-1 (210-302-R100, Alexis), anti-Daxx (D7810, Millipore Sigma), anti-GAPDH (Cell signaling 2118); Mouse monoclonal anti-p53 (OP43, Millipore Sigma), anti-PML (ab96051, Abcam), anti-Lamin A/C (MANLAC1, DSHB), anti-PAR (4335-MC-100, Trevigen), anti-HP1 γ (MAB3450, Chemicon), anti-DNMT3A (IMG-268A, Imgenex); Actin-Peroxidase antibody (Sigma A3854).

Immunofluorescence (IF). On day 8 post HIV infection, cells were washed with 1XPBS and fixed for 15 min with 2% paraformaldehyde (Electron Microscopy Sciences) in 1XPBS, then washed twice with 1XPBS, recovered with 70% ethanol, washed with 1XPBS and permeabilized for 15 min with 0.3% TritonX-100 (Sigma) in PBS. Cells were then incubated in blocking solution (0.2% fish gelatin, 0.5% BSA in 1XPBS) for 30 min, at room temperature (RT). Primary antibodies were diluted in blocking solution and applied on the cells for 1h at RT followed with 1xPBS washing. For 5hmc and 5mc staining, after the permeabilization and PBS-washing steps the cells were treated with 4N HCl for 30 min at room temperature. Cells were then washed with 1xPBS three times, incubated with 5-hmc or 5mc antibodies in blocking solution. Cells were further incubated with fluorescence-conjugated secondary antibodies in blocking solution for 1h, RT, counterstained with Dapi and mounted in Fluoromount-G medium (SouthernBiotech). Images were taken at Nikon Upright Microscope using 20X or 100X lens and processed with Adobe Photoshop CS6. Antibodies used in IF: mouse anti-p24 (ab9071, Abcam), rabbit anti-H3K4me3 (07-433, Millipore Sigma), rabbit anti-PML (A301167A, Bethyl), mouse anti-5mc (C15200081-100, Diagenode), rabbit anti-5hmc (39769, Active motif), goat anti-DAXX (sc-167A, Santa Cruz), AlexaFluor594 or AlexaFluor488 (Invitrogen). Original fluorescence images were captured with standardized acquisition parameters using a Nikon 80i upright microscope with ImagePro Plus software (Media Cybernetics). Fluorescence image intensity was quantified by gathering each set of images into a single multipoint, multichannel ND file using Nikon Elements AR software (Nikon Instruments) and analyzed together. For each individual image, the DAPI channel was used to define the size, shape and location for each nucleus, the outline was converted to a region of interest and applied to all available channels for that image. Mean intensity was then collected in each channel for each region of interest.

RNA extraction and quantitative RT-PCR. RNA was isolated from 2×10^6 cells using RNeasy plus mini Kit (Qiagen). Reverse transcription was performed with either random decamers or

HIV antisense-specific primers. HIV antisense qPCR was carried out using 4 specific primer pairs and the antisense reverse transcription cDNA, while cellular GUSB and HIV tat and nef qPCR was done using random decamer cDNA. Real-time PCR was performed with SYBR green probe in an ABI Prism 7900 and the delta Ct method for relative quantitation. Primers for HIV antisense-specific reverse transcription and RT-qPCR are listed in Supplement Table S2.

Acknowledgments

This work was supported by NIH grant R61/33 133696 (RGC, PML). We thank J. Skowronski and B. Hahn for constructs. We acknowledge assistance from Andreas Wiedmer and the Wistar Cancer Center Core Facilities in Imaging and Flow Cytometry, and the Immunology and Virology Cores of the Penn Center for AIDS Research (P30-AI045008).

References

1. Pitman MC, Lau JSY, McMahon JH, Lewin SR. 2018. Barriers and strategies to achieve a cure for HIV. *Lancet HIV* 5:e317-e328.
2. Rothenberger MK, Keele BF, Wietgreffe SW, Fletcher CV, Beilman GJ, Chipman JG, Khoruts A, Estes JD, Anderson J, Callisto SP, Schmidt TE, Thorkelson A, Reilly C, Perkey K, Reimann TG, Uday NS, Nganou Makamdop K, Stevenson M, Douek DC, Haase AT, Schacker TW. 2015. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. *Proc Natl Acad Sci U S A* 112:E1126-34.
3. Lamers SL, Rose R, Maidji E, Aagsa-Garcia M, Nolan DJ, Fogel GB, Salemi M, Garcia DL, Bracci P, Yong W, Commings D, Said J, Khanlou N, Hinkin CH, Sueiras MV, Mathisen G, Donovan S, Shiramizu B, Stoddart CA, McGrath MS, Singer EJ. 2016. HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads. *J Virol* 90:8968-83.
4. Eisele E, Siliciano RF. 2012. Redefining the viral reservoirs that prevent HIV-1 eradication. *Immunity* 37:377-88.
5. Kruize Z, Kootstra NA. 2019. The Role of Macrophages in HIV-1 Persistence and Pathogenesis. *Front Microbiol* 10:2828.
6. Wallet C, De Rovere M, Van Assche J, Daouad F, De Wit S, Gautier V, Mallon PWG, Marcello A, Van Lint C, Rohr O, Schwartz C. 2019. Microglial Cells: The Main HIV-1 Reservoir in the Brain. *Front Cell Infect Microbiol* 9:362.
7. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. 2009. The challenge of finding a cure for HIV infection. *Science* 323:1304-7.
8. Collman R, Hassan NF, Walker R, Godfrey B, Cutilli J, Hastings JC, Friedman H, Douglas SD, Nathanson N. 1989. Infection of monocyte-derived macrophages with human immunodeficiency virus type 1 (HIV-1). Monocyte-tropic and lymphocyte-tropic strains of HIV-1 show distinctive patterns of replication in a panel of cell types. *J Exp Med* 170:1149-63.
9. Rich EA, Chen IS, Zack JA, Leonard ML, O'Brien WA. 1992. Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1 (HIV-1). *J Clin Invest* 89:176-83.
10. Weinberg JB, Matthews TJ, Cullen BR, Malim MH. 1991. Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. *J Exp Med* 174:1477-1482.
11. Stevenson M, Brichacek B, Heinzinger N, Swindells S, Pirruccello S, Janoff E, Emerman M. 1995. Molecular basis of cell cycle dependent HIV-1 replication. Implications for control of virus burden. *Adv Exp Med Biol* 374:33-45.
12. Agosto LM, Yu JJ, Dai J, Kaletsky R, Monie D, O'Doherty U. 2007. HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. *Virology* 368:60-72.

- 432 13. Dai J, Agosto LM, Baytop C, Yu JJ, Pace MJ, Liszewski MK, O'Doherty U. 2009. Human
433 immunodeficiency virus integrates directly into naive resting CD4+ T cells but enters
434 naive cells less efficiently than memory cells. *J Virol* 83:4528-37.
- 435 14. Pace MJ, Graf EH, Agosto LM, Mexas AM, Male F, Brady T, Bushman FD, O'Doherty U.
436 2012. Directly infected resting CD4+T cells can produce HIV Gag without spreading
437 infection in a model of HIV latency. *PLoS Pathog* 8:e1002818.
- 438 15. Gendelman HE, Orenstein JM, Baca LM, Weiser B, Burger H, Kalter DC, Meltzer MS.
439 1989. The macrophage in the persistence and pathogenesis of HIV infection. *AIDS* 3:475-
440 495.
- 441 16. Collman R, Hassan NF, Walker R, Godfrey B, Cutilli J, Hastings JC, Friedman H, Douglas
442 SD, Nathanson N. 1989. Infection of monocyte-derived macrophages with human
443 immunodeficiency virus type 1 (HIV-1). Monocyte-tropic and lymphocyte-tropic strains
444 of HIV-1 show distinctive patterns of replication in a panel of cell types. *JExpMed*
445 170:1149-1163.
- 446 17. Sattentau QJ, Stevenson M. 2016. Macrophages and HIV-1: An Unhealthy Constellation.
447 *Cell Host Microbe* 19:304-10.
- 448 18. Abbas W, Tariq M, Iqbal M, Kumar A, Herbein G. 2015. Eradication of HIV-1 from the
449 macrophage reservoir: an uncertain goal? *Viruses* 7:1578-98.
- 450 19. Joseph SB, Arrildt KT, Sturdevant CB, Swanstrom R. 2015. HIV-1 target cells in the CNS. *J*
451 *Neurovirol* 21:276-89.
- 452 20. Churchill M, Nath A. 2013. Where does HIV hide? A focus on the central nervous system.
453 *Curr Opin HIV AIDS* 8:165-9.
- 454 21. Chen MF, Gill AJ, Kolson DL. 2014. Neuropathogenesis of HIV-associated neurocognitive
455 disorders: roles for immune activation, HIV blipping and viral tropism. *Curr Opin HIV*
456 *AIDS* 9:559-64.
- 457 22. Kumar A, Abbas W, Herbein G. 2014. HIV-1 latency in monocytes/macrophages. *Viruses*
458 6:1837-60.
- 459 23. Redel L, Le Douce V, Cherrier T, Marban C, Janossy A, Aunis D, Van Lint C, Rohr O,
460 Schwartz C. 2010. HIV-1 regulation of latency in the monocyte-macrophage lineage and
461 in CD4+ T lymphocytes. *J Leukoc Biol* 87:575-88.
- 462 24. Siliciano RF, Greene WC. 2011. HIV Latency. *Cold Spring Harb Perspect Med* 1.
- 463 25. Williams DW, Veenstra M, Gaskill PJ, Morgello S, Calderon TM, Berman JW. 2014.
464 Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV
465 associated neurocognitive disorders. *Curr HIV Res* 12:85-96.
- 466 26. Yadav A, Collman RG. 2009. CNS inflammation and macrophage/microglial biology
467 associated with HIV-1 infection. *J Neuroimmune Pharmacol* 4:430-47.
- 468 27. Mbonye U, Karn J. 2017. The Molecular Basis for Human Immunodeficiency Virus
469 Latency. *Annu Rev Virol* 4:261-285.
- 470 28. Boehm D, Ott M. 2017. Host Methyltransferases and Demethylases: Potential New
471 Epigenetic Targets for HIV Cure Strategies and Beyond. *AIDS Res Hum Retroviruses*
472 33:S8-S22.
- 473 29. Khoury G, Darcis G, Lee MY, Bouchat S, Van Driessche B, Purcell DFJ, Van Lint C. 2018.
474 The Molecular Biology of HIV Latency. *Adv Exp Med Biol* 1075:187-212.

- 475 30. Mbonye U, Karn J. 2014. Transcriptional control of HIV latency: cellular signaling
476 pathways, epigenetics, happenstance and the hope for a cure. *Virology* 454-455:328-39.
- 477 31. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, Hahn BH. 1991. Molecular
478 characterization of human immunodeficiency virus type 1 cloned directly from
479 uncultured human brain tissue: identification of replication-competent and -defective
480 viral genomes. *J Virol* 65:3973-85.
- 481 32. Jordan A, Bisgrove D, Verdin E. 2003. HIV reproducibly establishes a latent infection
482 after acute infection of T cells in vitro. *EMBO J* 22:1868-77.
- 483 33. Rafati H, Parra M, Hakre S, Moshkin Y, Verdin E, Mahmoudi T. 2011. Repressive LTR
484 nucleosome positioning by the BAF complex is required for HIV latency. *PLoS Biol*
485 9:e1001206.
- 486 34. Verdin E, Paras P, Jr., Van Lint C. 1993. Chromatin disruption in the promoter of human
487 immunodeficiency virus type 1 during transcriptional activation. *EMBO J* 12:3249-59.
- 488 35. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. 2009. Epigenetic regulation of
489 HIV-1 latency by cytosine methylation. *PLoS Pathog* 5:e1000495.
- 490 36. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. 2006. NF-kappaB
491 p50 promotes HIV latency through HDAC recruitment and repression of transcriptional
492 initiation. *EMBO J* 25:139-49.
- 493 37. Turner AW, Margolis DM. 2017. Chromatin Regulation and the Histone Code in HIV
494 Latency. *Yale J Biol Med* 90:229-243.
- 495 38. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A,
496 Wernig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber SL, Lander ES. 2006. A
497 bivalent chromatin structure marks key developmental genes in embryonic stem cells.
498 *Cell* 125:315-26.
- 499 39. Matsumura Y, Nakaki R, Inagaki T, Yoshida A, Kano Y, Kimura H, Tanaka T, Tsutsumi S,
500 Nakao M, Doi T, Fukami K, Osborne TF, Kodama T, Aburatani H, Sakai J. 2015.
501 H3K4/H3K9me3 Bivalent Chromatin Domains Targeted by Lineage-Specific DNA
502 Methylation Pauses Adipocyte Differentiation. *Mol Cell* 60:584-96.
- 503 40. He J, Fu X, Zhang M, He F, Li W, Abdul MM, Zhou J, Sun L, Chang C, Li Y, Liu H, Wu K,
504 Babarinde IA, Zhuang Q, Loh YH, Chen J, Esteban MA, Hutchins AP. 2019. Transposable
505 elements are regulated by context-specific patterns of chromatin marks in mouse
506 embryonic stem cells. *Nat Commun* 10:34.
- 507 41. Ninova M, Fejes Toth K, Aravin AA. 2019. The control of gene expression and cell
508 identity by H3K9 trimethylation. *Development* 146.
- 509 42. Kobayashi-Ishihara M, Terahara K, Martinez JP, Yamagishi M, Iwabuchi R, Brander C, Ato
510 M, Watanabe T, Meyerhans A, Tsunetsugu-Yokota Y. 2018. HIV LTR-Driven Antisense
511 RNA by Itself Has Regulatory Function and May Curtail Virus Reactivation From Latency.
512 *Front Microbiol* 9:1066.
- 513 43. Saayman S, Ackley A, Turner AW, Famiglietti M, Bosque A, Clemson M, Planelles V,
514 Morris KV. 2014. An HIV-encoded antisense long noncoding RNA epigenetically
515 regulates viral transcription. *Mol Ther* 22:1164-1175.
- 516 44. Groh S, Schotta G. 2017. Silencing of endogenous retroviruses by heterochromatin. *Cell*
517 *Mol Life Sci* 74:2055-2065.

- 518 45. Tavalai N, Stamminger T. 2009. Interplay between Herpesvirus Infection and Host
519 Defense by PML Nuclear Bodies. *Viruses* 1:1240-64.
- 520 46. Wang Q, Su L. 2019. Vpr Enhances HIV-1 Env Processing and Virion Infectivity in
521 Macrophages by Modulating TET2-Dependent IFITM3 Expression. *mBio* 10.
- 522 47. Lv L, Wang Q, Xu Y, Tsao LC, Nakagawa T, Guo H, Su L, Xiong Y. 2018. Vpr Targets TET2
523 for Degradation by CRL4(VprBP) E3 Ligase to Sustain IL-6 Expression and Enhance HIV-1
524 Replication. *Mol Cell* 70:961-970 e5.
- 525 48. Herrtwich L, Nanda I, Evangelou K, Nikolova T, Horn V, Sagar, Erny D, Stefanowski J,
526 Rogell L, Klein C, Gharun K, Follo M, Seidl M, Kremer B, Munke N, Senges J, Fliegauf M,
527 Aschman T, Pfeifer D, Sarrazin S, Sieweke MH, Wagner D, Dierks C, Haaf T, Ness T, Zaiss
528 MM, Voll RE, Deshmukh SD, Prinz M, Goldmann T, Holscher C, Hauser AE, Lopez-
529 Contreras AJ, Grun D, Gorgoulis V, Diefenbach A, Henneke P, Triantafyllopoulou A. 2016.
530 DNA Damage Signaling Instructs Polyploid Macrophage Fate in Granulomas. *Cell*
531 167:1264-1280 e18.
- 532 49. Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M,
533 Janotta F, Aksamit A, Martin MA, Fauci AS. 1986. Detection of AIDS virus in
534 macrophages in brain tissue from AIDS patients with encephalopathy. *Science* 233:1089-
535 93.
- 536 50. Budka H. 1986. Multinucleated giant cells in brain: a hallmark of the acquired immune
537 deficiency syndrome (AIDS). *Acta Neuropathol* 69:253-8.
- 538 51. Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C, Aunis D, Rohr O.
539 2007. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1
540 transcriptional silencing. *EMBO J* 26:412-23.
- 541 52. du Chene I, Basyuk E, Lin YL, Triboulet R, Knezevich A, Chable-Bessia C, Mettling C,
542 Baillat V, Reynes J, Corbeau P, Bertrand E, Marcello A, Emiliani S, Kiernan R, Benkirane
543 M. 2007. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1
544 transcriptional silencing and post-integration latency. *EMBO J* 26:424-35.
- 545 53. Tchasovnikarova IA, Timms RT, Matheson NJ, Wals K, Antrobus R, Gottgens B, Dougan G,
546 Dawson MA, Lehner PJ. 2015. GENE SILENCING. Epigenetic silencing by the HUSH
547 complex mediates position-effect variegation in human cells. *Science* 348:1481-1485.
- 548 54. Cherrier T, Le Douce V, Eilebrecht S, Riclet R, Marban C, Dequiedt F, Goumon Y, Paillart
549 JC, Mericskay M, Parlakian A, Bausero P, Abbas W, Herbein G, Kurdistani SK, Grana X,
550 Van Driessche B, Schwartz C, Candolfi E, Benecke AG, Van Lint C, Rohr O. 2013. CTIP2 is a
551 negative regulator of P-TEFb. *Proc Natl Acad Sci U S A* 110:12655-60.
- 552 55. Le Douce V, Colin L, Redel L, Cherrier T, Herbein G, Aunis D, Rohr O, Van Lint C, Schwartz
553 C. 2012. LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing. *Nucleic
554 Acids Res* 40:1904-15.
- 555 56. Rohr O, Marban C, Aunis D, Schaeffer E. 2003. Regulation of HIV-1 gene transcription:
556 from lymphocytes to microglial cells. *J Leukoc Biol* 74:736-49.
- 557 57. Cherrier T, Suzanne S, Redel L, Calao M, Marban C, Samah B, Mukerjee R, Schwartz C,
558 Gras G, Sawaya BE, Zeichner SL, Aunis D, Van Lint C, Rohr O. 2009. p21(WAF1) gene
559 promoter is epigenetically silenced by CTIP2 and SUV39H1. *Oncogene* 28:3380-9.
- 560 58. Le Douce V, Forouzanfar F, Eilebrecht S, Van Driessche B, Ait-Ammar A, Verdikt R,
561 Kurashige Y, Marban C, Gautier V, Candolfi E, Benecke AG, Van Lint C, Rohr O, Schwartz

- C. 2016. HIC1 controls cellular- and HIV-1- gene transcription via interactions with CTIP2 and HMGA1. *Sci Rep* 6:34920.
59. Blazkova J, Trejbalova K, Gondois-Rey F, Halfon P, Philibert P, Guiguen A, Verdin E, Olive D, Van Lint C, Hejnar J, Hirsch I. 2009. CpG methylation controls reactivation of HIV from latency. *PLoS Pathog* 5:e1000554.
60. Meldi KM, Figueroa ME. 2015. Cytosine modifications in myeloid malignancies. *Pharmacol Ther* 152:42-53.
61. Singh RK, Diaz PE, Binette F, Nasonkin IO. 2018. Immunohistochemical Detection of 5-Methylcytosine and 5-Hydroxymethylcytosine in Developing and Postmitotic Mouse Retina. *J Vis Exp* doi:10.3791/58274.
62. Muthumani K, Choo AY, Zong WX, Madesh M, Hwang DS, Premkumar A, Thieu KP, Emmanuel J, Kumar S, Thompson CB, Weiner DB. 2006. The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. *Nat Cell Biol* 8:170-9.
63. Lee C, Liu QH, Tomkowicz B, Yi Y, Freedman BD, Collman RG. 2003. Macrophage activation through CCR5- and CXCR4-mediated gp120-elicited signaling pathways. *J Leukoc Biol* 74:676-82.
64. McNally AK, Anderson JM. 2011. Macrophage fusion and multinucleated giant cells of inflammation. *Adv Exp Med Biol* 713:97-111.
65. Herrtwich L, Nanda I, Evangelou K, Nikolova T, Horn V, Sagar, Erny D, Stefanowski J, Rogell L, Klein C, Gharun K, Follo M, Seidl M, Kremer B, Munke N, Senges J, Fliegauf M, Aschman T, Pfeifer D, Sarrazin S, Sieweke MH, Wagner D, Dierks C, Haaf T, Ness T, Zaiss MM, Voll RE, Deshmukh SD, Prinz M, Goldmann T, Holscher C, Hauser AE, Lopez-Contreras AJ, Grun D, Gorgoulis V, Diefenbach A, Henneke P, Triantafyllopoulou A. 2018. DNA Damage Signaling Instructs Polyploid Macrophage Fate in Granulomas. *Cell* 174:1325-1326.
66. Geis FK, Goff SP. 2019. Unintegrated HIV-1 DNAs are loaded with core and linker histones and transcriptionally silenced. *Proc Natl Acad Sci U S A* 116:23735-23742.
67. Machida S, Depierre D, Chen HC, Thenin-Houssier S, Petitjean G, Doyen CM, Takaku M, Cuvier O, Benkirane M. 2020. Exploring histone loading on HIV DNA reveals a dynamic nucleosome positioning between unintegrated and integrated viral genome. *Proc Natl Acad Sci U S A* 117:6822-6830.
68. Hamid FB, Kim J, Shin CG. 2017. Distribution and fate of HIV-1 unintegrated DNA species: a comprehensive update. *AIDS Res Ther* 14:9.
69. Brinkman AB, Roelofsen T, Pennings SW, Martens JH, Jenuwein T, Stunnenberg HG. 2006. Histone modification patterns associated with the human X chromosome. *EMBO Rep* 7:628-34.
70. Kim A, Kiefer CM, Dean A. 2007. Distinctive signatures of histone methylation in transcribed coding and noncoding human beta-globin sequences. *Mol Cell Biol* 27:1271-9.
71. Vakoc CR, Mandat SA, Olenchok BA, Blobel GA. 2005. Histone H3 lysine 9 methylation and HP1gamma are associated with transcription elongation through mammalian chromatin. *Mol Cell* 19:381-91.

Lu et al, 2022

HIV epigenetic landscape in macrophages

- 605 72. Wiencke JK, Zheng S, Morrison Z, Yeh RF. 2008. Differentially expressed genes are
606 marked by histone 3 lysine 9 trimethylation in human cancer cells. *Oncogene* 27:2412-
607 21.
- 608 73. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L,
609 Washburn MP, Skowronski J. 2011. Vpx relieves inhibition of HIV-1 infection of
610 macrophages mediated by the SAMHD1 protein. *Nature* 474:658-61.
- 611 74. Chau CM, Lieberman PM. 2004. Dynamic chromatin boundaries delineate a latency
612 control region of Epstein-Barr virus. *J Virol* 78:12308-19.
613

Figure Legends

Figure 1. Histone modifications across the HIV genome in MDM, CD4 T cells and JLAT

8.4 cells. A) Schematic of HIV genome and positions of primers used for ChIP and DIP. **B)** ChIP-qPCR analysis of the HIV genome in MDM, CD4 T cells, or JLAT 8.4 cells for H3K4me3, H3K9me3, H3K9ac, H3K9me2, H3K27ac, or H3K27me3 using primers spaced across the genome as indicated. Cellular control primers targeted the Actin and GAPDH promoters, and 10q CTCF and 10q TERRA transcript regions. Note that primer stes Nuc0, Nuc1, A, B, S, T target sequences in both 5' and 3' LTRs but are depicted graphically with one or the other. Error bars are sdm for 3 technical replicates.

Figure 2. ChIP-qPCR focusing on HIV LTR. A) Schematic of HIV 5' LTR with adjacent nucleosome 2 and positions of primers used in Fig 2B. Solid line represents LTR DNA, and dashed line represents HIV genomic region downstream of 5' LTR. Primers that amplify sequence duplicated in 5' and 3' LTRs are listed. **B)** ChIP-qPCR data from Fig 1 was re-graphed to directly compare enrichments of each histone modification across the LTR region and adjacent nucleosome 2 site for MDM, CD4, and JLAT8.4. Error bars are sdm for 3 technical replicates.

Figure 3. Antisense RNA transcripts of HIV in MDM and CD4 infection. A) Schematic of HIV genome showing position of three HIV-specific antisense reverse transcription primers (AS-RT1,2, or 3) and four qPCR primer pairs (1, 2, 3, and 4) used for antisense transcript quantification. **B)** RT-qPCR of antisense transcripts in uninfected and YU2-infected CD4 T cells and MDM, calculated relative to cellular GUSB sense transcript. **C)** RT-qPCR of antisense transcripts in YU2-infected CD4 T cells and MDM with or with addition of RT. **D)** Sense transcription of nef or tat for same infection and RNA samples as shown in panel B.

Figure 4. DNA immunoprecipitation (DIP) assay for 5mc or 5hmc across the HIV genome for infected MDM, CD4 T cells, or JLAT 8.4 cells. MeDIP for 5mC (left panels, orange bars) or hmeDIP for 5hmc (right panels, green bars) or control IgG were analyzed using PCR primers across HIV genome, as indicated in Fig. 1A. Cellular gene control sites at 10q or XqYq TERRA or promoter regions for Actin or GAPDH.

Figure 5. Western blot analysis of MDM and CD4 T cells with HIV-1 YU2 or mock infection. **A)** Westerns were probed for a panel of histone modifications H3K9me3, H3K9me2, H3K27me3, H3K4me3, H3ac, H3, H2B, and HP1 γ . **B)** Westerns probed for PML, Daxx, DNMT3A, TET2, Lamin B1, Lamin A/C. **C)** Westerns probed for p53, PARP1, PAR, Actin or GAPDH.

Figure 6. Immunofluorescence microscopy of MDM with HIV-1 YU2 or mock infection. **A)** YU2 or mock infected MDM stained with H3K4me3 (green) or HIV protein p24 (red), merge with Dapi (blue). **B)** 5-hmc (green), 5-mc (red) or merge with Dapi (blue). **C)** PML (green), p24 (red), or merge with Dapi (blue). **D)** PML (green), DAXX (red), merge with Dapi (blue). The images were taken with 20X (**A – C**) or 100X (**D**) lens. Scale bar = 10 μ m. **E)** Quantification of fluorescence intensity for images represented in panels A-D are provided for cells n>100 with distribution around mean intensity. P values were determined by two-tailed student-t test. ****p<0.0001. **F)** IF for 5hmc in MDM mock (top panels) or YU2 infected (lower panels) with 5hmc (green) or DAPI (blue, merge). Images taken with 20x lens.

Figure 7. Model of HIV epigenetic regulation. Summary of histone tail modifications associated with LTR region in HIV infected MDM, CD4 T cells and JLAT 8.4 infection.

Figure 1

Figure 2

Figure 3

A

Antisense RT primers

B

C

D

Figure 4

Figure 5

688 **Figure 6**

689

Figure 7

Lu et al, 2022

HIV epigenetic landscape in macrophages

Supplemental Figure Legends

Supplemental Figure S1. ChIP-qPCR controls. ChIP-qPCR of HIV genome (as in Figure 1) showing control IgG and total H3 antibody in MDM, CD4, and JLAT 8.4.

Supplemental Figure S1.

Supplemental Table S1 HIV genomic primers.

A. Genomic primers for HIV YU2 strain.

CACTGACCTTTGGATGGTGCTT	Nuc_0_5'
TGCATTGGCCTCTTCTATCTTCT	Nuc_0_3'
AGAAGGGTTAGAGTGGAGGTTTGA	A_5'
TCTCGGGCCACGTGATG	A_3'
ATCTGAGCCTGGGAGCTCTCT	Nuc_1_5'
AGGCAAGCTTTATTGAGGCTTAAG	Nuc_1_3'
CGACTGGTGAGTACGCCAAA	B_5'
CGCACCCATCTCTCTCCTTCT	B_3'
CAGCCAGGTCAGCCAAAATT	C_5'
TGGCCTGATGTACCATTTCG	C_3'
GAGCAAGCTTCACAGGAGGTAAA	D_5'
TCTGGGTTTCGCATTTTGA	D_3'
GCCAACAGCCCCATCAGA	E_5'
CTGAGAGGGAGTTGTTGTCTCTTCT	E_3'
GGATGGCCCAAAAGTTAAACAA	F_5'
TTTTCAGGCCCAATTTTGA	F_3'
CTTAGAAATAGGGCAGCATAGAACAA	G_5'
GGTAAATCCCCACCTCAACAGA	G_3'
AAACAGGGAAATTCTAAAAGAACCA	H_5'
TTCTGTATTTCTGCTATCAAGTCTTTTGA	H_3'
TCTCCCTAACTGACACAACAAATCA	I_5'
CCGAATCCTGCAAAGCTAGATAA	I_3'
GCAGAAGTTATTCCAGCAGAGACA	J_5'
GGCCATCTTCCTGCTAATTTTAAG	J_3'
AACAGATGGCAGGTGATGATTG	K_5'
TTTACTAACTTTTCCATGCTCTAATCCT	K_3'
GCACAATGAATGGACACTAGAGCTT	L_5'
CATGGCCTAGGAAAATGTCTAACA	L_3'
GCAGAAGACAGTGGCAATGAGA	M_5'
CCCTTTCCACAAGTGCTGATAAT	M_3'
ATGGTAGAACAAATGCATGAGGATAT	N_5'
GGAGTTAATTTTACACATGGCTTTAGG	N_3'
GGCAGTCTAGCAGAAGAAGAGATAGTAA	O_5'
CTTGTATTGTTGTTGGGTCTTGTAACA	O_3'
CCCATCAGAGGACAAATTAGATGTT	P_5'
CGTGTCCTTACCACCATCTCTTG	P_3'
GCACCACTACTGTGCCTTGGA	Q_5'
TCATGTTATCCCAAATTTCAATTCAG	Q_3'

TGGATGGCTTCTTAGCAATTATCTG	R_5'
AGCGGTGGTAGCTGAAAAGG	R_3'
GGGACTGGAAGGGCTAATTCA	S_5'
TGGTAGACCCACAGATCAAGGA	S_3'
GCATCCGGAGTACTACAAGAACTGAT	T_5'
CCACGCTTCCCTGGAAAGT	T_3'

B. Genomic primers for HIV HXB2 strain (JLAT 8.4).

CCAGGGCCAGGGATCAG	Nuc_0_5'
GCTCAACTGGTACTAGCTTGTAGCA	Nuc_0_3'
AGAAGTGTTAGAGTGGAGGTTTGACA	A_5'
AGCTCTCGGGCCATGTGA	A_3'
ATCTGAGCCTGGGAGCTCTCT	Nuc_1_5'
AGGCAAGCTTTATTGAGGCTTAAG	Nuc_1_3'
CGACTGGTGAGTACGCCAAA	B_5'
CGCACCCATCTCTCTCCTTCT	B_3'
TGGGTAAAAGTAGTAGAAGAGAAGGCTTT	C_5'
GGCTCCTTCTGATAATGCTGAAA	C_3'
GAGCAAGCTTCACAGGAGGTAAA	D_5'
TCTGGGTTTCGCATTTTGGA	D_3'
CAGGAGCCGATAGACAAGGAA	E_5'
GGGTCGTTGCCAAAGAGTGA	E_3'
GGGCCTGAAAATCCATACAATACT	F_5'
CCAGAAGTCTTGAGTTCTCTTATTAAGTTC	F_3'
GGGACTTACCACACCAGACAAAA	G_5'
GAGTTCATAACCCATCCAAAGGA	G_3'
GAAAACAGGAAAATATGCAAGAATGA	H_5'
TGCACTGCCTCTGTTAATTGTTTTA	H_3'
CAAGCACAACCAGATCAAAGTGA	I_5'
GCCAGATAGACCTTTTCTTTTATT	I_3'
GCAGGAAGATGGCCAGTAAAAA	J_5'
CCGTAGCACCGGTGAAATTG	J_3'
GCAAGTAGACAGGATGAGGATTAGAA	K_5'
CCCCTAGCTTTCCTGAAACA	K_3'
ATTTTCCTAGGATTTGGCTCCAT	L_5'
GCCCAAGTATCCCCATAAGTTTC	L_3'
AAGACAGTGGCAATGAGAGTGAAG	M_5'
CATCAACATCCCAAGGAGCAT	M_3'
GGTAAGGTGCAGAAAGAATATGCA	N_5'
TGGGAATTGGCTCAAAGGAT	N_3'

Lu et al, 2022

HIV epigenetic landscape in macrophages

CAGGGAGAGCATTGTTACAATAGG	O_5'
TGTTCTCTTAATTTGCTAGCTATCTGTTTT	O_3'
CAGACCTGGAGGAGGAGATATGA	P_5'
GGTGCTACTCCTAATGGTTCAATTTT	P_3'
GGAGTGGGACAGAGAAATTAACAATT	Q_5'
GCTGGTTTTGCGATTCTTCAA	Q_3'
GGGTGGGAAGCCCTCAAAT	R_5'
GCACTATTCTTTAGTTCCTGACTCCAA	R_3'
GGGCTAATCACTCCCAAAGAA	S_5'
GGAAGTAGCCTTGTGTGTGGTAGA	S_3'
TGCATCCGGAGTACTTCAAGAA	T_5'
CACGCCTCCCTGGAAAGTC	T_3'

715

Supplemental Table S2 RT-qPCR primers.

CCTAGTATAAACAATGAGACACCAGGG	AS_RT_1 (2944)
CACTCCCAACAAAGACAAGATA	AS_RT_2 (15)
CTCCCATGTAGAATAAAACAAATTA	AS_RT_3 (7431)
TGAGACAACATCTGTTGAGGTGGG	YU2_3161_PRIMER1_F
GGCTGTACTGTCCATTTATCAGGA	YU2_3275_PRIMER1_R
TTGTTCTGCTGTTGCACTA	YU2_7846_PRIMER2_F
AGCTTTGTTCTTGGGTTCT	YU2_7733_PRIMER2_R
CTTTCCGCTGGGGACTTTCCAGG	YU2_351_PRIMER3_F
CCAGAGAGACCCAGTACAGGCCAAAAGCAG	YU2_461_PRIMER3_R
GTTTCAGACCCACCTCCCAG	YU2_8333_PRIMER4_F
TGGACCGGATCTGTCTCTGT	YU2_8426_PRIMER4_R
CGGCGACTGAATTGGGTG	TAT_F
CGGCGACTGGAAGAAGCG	NEF_F
GTCTCTCTCTCCACCTTCTTCTTC	TAT_NEF_R
CGCCCTGCCTATCTGTATTC	GUSB_F
TCCCCACAGGGAGTGTGTAG	GUSB_R

Lu et al, 2022

HIV epigenetic landscape in macrophages

723

724